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Academic chartered data safety
committees versus industry sponsored
data safety committees: The need for
different recommendations
Dear Editor,
We read with great interest the recently published
paper by Calis et al.1 We applaud the authors and the
working group for developing this important set of rec-
ommendations for data monitoring committees
(DMC). Recommendations for organizing a DMC are
long overdue. Our academic institution has had a for-
mal DMC for many years which administratively
reports to an academic official who directs the research
efforts. It has a formal charter and broad membership
that includes clinicians, clinical trial specialists, and a
biostatistician. It accepts for review studies that require
a DMC (usually phase II or III trials) and are not
sponsored by industry, which usually set up their own
DMC. Most studies are supported by the institution,
US Government research funding sources (e.g.
National Institutes of Health (NIH), Centers for
Disease Control and Prevention), or research
foundations.
The recommendations by Calis et al. appear to be
focused on a DMC organized by industry (e.g. drug
company or device manufacturer). However, a standing
DMC organized by an academic institution often oper-
ates using a different set of rules with regard to the fol-
lowing: (1) reporting structure, (2) independence, and
(3) conflicts of interest. In addition, and in contrast to
an industry-sponsored DMC, an academic DMC often
determines whether such oversight is necessary and is
in the best interest of subject safety. All clinical trials
need a plan to assure subject safety, but safety and trial
integrity in low risk or small trials may be better served
by an independent safety monitor with direct reporting
to an Institutional Review Board (IRB). Finally, there
is an intermediate type of academic DMC; a study-
specific DMC constituted for a multicenter study run
through academic institutions and funded by the NIH
or a research foundation.
First, Calis et al. recommended that DMC reports
be ‘‘provided to a steering committee or sponsor leader-
ship group authorized to act on these recommenda-
tions, and not to those directly involved with
implementation of the trial.’’ At our academic institu-
tion, our DMC reports are sent to the principal investi-
gator (PI) and then forwarded by the PI to our IRB.
The IRB has the authority to require modifications in
the study, suspend enrollment in the study, or termi-
nate the study. The PI may also forward the DMC
report to the funding source for the study.
Second, Calis et al. recommended that ‘‘indepen-
dence from the trial sponsor is critical for the DMC to
fulfill its central role of protecting vulnerable study par-
ticipants from unpredictable harm that may arise dur-
ing the course of a trial.’’ Typically, industry-sponsored
DMCs are composed of members who receive no funds
(e.g. employment, research funds) or benefits (e.g.
stock) from the company. However, academic DMCs
are typically composed of faculty and employees of the
academic institution. Independence is assured, in part,
by policies similar to those that govern the academic
IRB that prohibit interference in the functioning of the
DMC. We are unaware of any academic DMC that
includes only members who receive no funds or benefits
from the academic institution. For the intermediate
type of DMC, members are generally not from the cen-
ters conducting the study but will usually have their
own funding from the NIH and are thus not strictly
independent from the trial sponsor.
Finally, Calis et al. recommended that
Conflict of interest must be regularly disclosed, assessed,
and managed for all DMC members..Activities or rela-
tionships deemed to have the potential to undermine inde-
pendence of DMC members may result in disqualification
from DMC service; therefore, both actual and perceived
conflicts should be disclosed. Even the perception of a con-
flict of interest can damage the credibility of the DMC and
raise questions about its conduct and recommendations.
At academic DMCs, all members routinely disclose
potential conflicts. Members with a close relationship
to the research or investigators (e.g. co-investigator,
mentor, etc.) abstain from participating in the review.
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However, members in the same department or school
are usually permitted to participate in the review.
Again, we thank Calis and his collaborators for this
important paper. However, we think the recommenda-
tions should be revised to take into account the unique
features of an academic DMC.
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